Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

Fig. 5

The expression level of IFI44L correlates with clinical staging, RFS, and OS in HCC patients. a Representative examples of the expression levels of IFI44L protein determined by IHC of clinical specimens. b The mRNA expression level of IFI44L correlates with RFS in 217HCC patients. c The mRNA expression level of IFI44L correlates with OS in 217 HCC patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us